0.35 USD
▼-0.02-4.30%
盘后 0.29 -18.07%
2026-11-20
市值
$2.69M
市盈率
—
EPS
-0.53
股息率
—
52 周区间
0.35 – 1.43
成交量
90.62K
Beta
2.20
目标价
—
52W 低 0.3552W 高 1.43
价格走势
公司简介
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ...